 Alexander Burnett
Concepts (195)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laparoscopy | 7 | 2024 | 170 | 2.080 |
Why?
| | Endometrial Neoplasms | 8 | 2024 | 137 | 1.920 |
Why?
| | Uterine Cervical Neoplasms | 12 | 2022 | 276 | 1.740 |
Why?
| | Lymph Node Excision | 5 | 2024 | 138 | 1.540 |
Why?
| | Neoplasm Staging | 8 | 2024 | 749 | 0.920 |
Why?
| | Obesity, Morbid | 2 | 2023 | 74 | 0.920 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 4 | 0.900 |
Why?
| | Whole-Body Irradiation | 2 | 2014 | 129 | 0.870 |
Why?
| | Gynecologic Surgical Procedures | 4 | 2009 | 28 | 0.870 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2024 | 118 | 0.860 |
Why?
| | Metformin | 2 | 2020 | 63 | 0.640 |
Why?
| | Hypoglycemic Agents | 2 | 2020 | 169 | 0.610 |
Why?
| | Interleukin-11 | 2 | 2013 | 5 | 0.530 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2016 | 626 | 0.490 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2014 | 19 | 0.470 |
Why?
| | Prescription Drugs | 1 | 2014 | 38 | 0.460 |
Why?
| | Hysterectomy | 4 | 2023 | 88 | 0.450 |
Why?
| | Uterine Neoplasms | 7 | 2007 | 60 | 0.450 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 85 | 0.440 |
Why?
| | Radiation Tolerance | 1 | 2014 | 83 | 0.440 |
Why?
| | Radiation-Protective Agents | 1 | 2013 | 72 | 0.430 |
Why?
| | Obesity | 2 | 2016 | 1096 | 0.420 |
Why?
| | Robotics | 2 | 2010 | 41 | 0.410 |
Why?
| | Female | 32 | 2024 | 26560 | 0.400 |
Why?
| | Organotechnetium Compounds | 1 | 2011 | 6 | 0.380 |
Why?
| | Lymphedema | 1 | 2011 | 43 | 0.360 |
Why?
| | Vulvar Neoplasms | 1 | 2011 | 58 | 0.350 |
Why?
| | Lower Extremity | 1 | 2011 | 92 | 0.350 |
Why?
| | Radiopharmaceuticals | 1 | 2011 | 204 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2011 | 330 | 0.340 |
Why?
| | Cystadenocarcinoma, Papillary | 5 | 2006 | 14 | 0.320 |
Why?
| | Humans | 34 | 2024 | 49898 | 0.300 |
Why?
| | Adult | 19 | 2024 | 13346 | 0.300 |
Why?
| | Fertility | 2 | 2009 | 28 | 0.300 |
Why?
| | Aged | 16 | 2024 | 9447 | 0.290 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 32 | 0.290 |
Why?
| | Retrospective Studies | 5 | 2023 | 6123 | 0.290 |
Why?
| | Middle Aged | 18 | 2024 | 12285 | 0.280 |
Why?
| | Vagina | 2 | 2023 | 44 | 0.280 |
Why?
| | Cervix Uteri | 1 | 2006 | 42 | 0.260 |
Why?
| | Adenocarcinoma | 1 | 2009 | 401 | 0.250 |
Why?
| | Topotecan | 1 | 2005 | 17 | 0.240 |
Why?
| | Polyethylene Glycols | 1 | 2005 | 85 | 0.230 |
Why?
| | Genital Neoplasms, Female | 1 | 2004 | 41 | 0.230 |
Why?
| | Postoperative Complications | 1 | 2011 | 1018 | 0.230 |
Why?
| | Ovarian Neoplasms | 4 | 2014 | 450 | 0.220 |
Why?
| | Feasibility Studies | 2 | 2024 | 382 | 0.220 |
Why?
| | Doxorubicin | 1 | 2005 | 233 | 0.210 |
Why?
| | Uterus | 1 | 2023 | 87 | 0.210 |
Why?
| | Lymph Nodes | 1 | 2004 | 257 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2007 | 994 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2011 | 824 | 0.200 |
Why?
| | Aged, 80 and over | 5 | 2016 | 3136 | 0.190 |
Why?
| | Prospective Studies | 3 | 2024 | 2345 | 0.180 |
Why?
| | Intestines | 2 | 2013 | 169 | 0.170 |
Why?
| | Carcinoma | 2 | 2011 | 139 | 0.150 |
Why?
| | Cell Proliferation | 2 | 2020 | 986 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2007 | 1175 | 0.140 |
Why?
| | Cancer Vaccines | 3 | 2014 | 78 | 0.140 |
Why?
| | Dendritic Cells | 3 | 2014 | 133 | 0.140 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2020 | 35 | 0.140 |
Why?
| | Cystadenocarcinoma, Serous | 3 | 2005 | 71 | 0.140 |
Why?
| | Enterotoxins | 2 | 2007 | 12 | 0.130 |
Why?
| | Pregnancy | 1 | 2023 | 2468 | 0.130 |
Why?
| | Aromatase Inhibitors | 2 | 2007 | 14 | 0.130 |
Why?
| | Nitriles | 2 | 2007 | 52 | 0.130 |
Why?
| | Kallikreins | 2 | 2006 | 18 | 0.130 |
Why?
| | Mice | 4 | 2014 | 5658 | 0.130 |
Why?
| | Triazoles | 2 | 2007 | 112 | 0.120 |
Why?
| | Receptor, erbB-2 | 2 | 2005 | 74 | 0.120 |
Why?
| | Neoplasms | 1 | 2005 | 1233 | 0.120 |
Why?
| | Medical Oncology | 2 | 2006 | 95 | 0.120 |
Why?
| | Lethal Dose 50 | 1 | 2014 | 12 | 0.120 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 16 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2014 | 70 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 168 | 0.110 |
Why?
| | Ascites | 1 | 2014 | 28 | 0.110 |
Why?
| | Safety | 1 | 2014 | 77 | 0.110 |
Why?
| | Survival Analysis | 2 | 2013 | 670 | 0.110 |
Why?
| | Stomach | 1 | 2014 | 79 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 1 | 2013 | 47 | 0.110 |
Why?
| | Carcinoma, Endometrioid | 2 | 2010 | 38 | 0.100 |
Why?
| | Incidence | 1 | 2016 | 986 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 157 | 0.100 |
Why?
| | Administration, Oral | 1 | 2013 | 433 | 0.100 |
Why?
| | Papillomaviridae | 3 | 2013 | 102 | 0.100 |
Why?
| | Animals | 5 | 2014 | 13100 | 0.100 |
Why?
| | Cytokines | 1 | 2014 | 607 | 0.090 |
Why?
| | Arkansas | 1 | 2016 | 1987 | 0.090 |
Why?
| | Cerclage, Cervical | 1 | 2009 | 8 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2011 | 5176 | 0.080 |
Why?
| | Estrogens | 1 | 2011 | 222 | 0.080 |
Why?
| | Gene Amplification | 2 | 2005 | 57 | 0.080 |
Why?
| | Genes, erbB-2 | 2 | 2005 | 8 | 0.080 |
Why?
| | Male | 4 | 2014 | 25437 | 0.080 |
Why?
| | Carcinoma, Papillary | 2 | 2005 | 49 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2007 | 347 | 0.070 |
Why?
| | Melanoma | 1 | 2011 | 281 | 0.070 |
Why?
| | Intestinal Diseases | 1 | 2007 | 26 | 0.070 |
Why?
| | Leiomyosarcoma | 1 | 2007 | 23 | 0.070 |
Why?
| | Clostridium perfringens | 1 | 2007 | 6 | 0.070 |
Why?
| | Carcinosarcoma | 1 | 2007 | 18 | 0.070 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 81 | 0.070 |
Why?
| | Endometrium | 2 | 2020 | 40 | 0.070 |
Why?
| | Infertility, Female | 1 | 2006 | 18 | 0.070 |
Why?
| | Oncogene Proteins, Viral | 1 | 2005 | 52 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 118 | 0.060 |
Why?
| | Dysgerminoma | 1 | 2004 | 3 | 0.060 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2004 | 6 | 0.060 |
Why?
| | Patient Selection | 1 | 2006 | 254 | 0.060 |
Why?
| | Gynecology | 1 | 2004 | 49 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 1 | 2005 | 158 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2005 | 265 | 0.060 |
Why?
| | Lymphatic Metastasis | 1 | 2004 | 226 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 380 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 457 | 0.050 |
Why?
| | Adolescent | 4 | 2013 | 6414 | 0.050 |
Why?
| | Immunohistochemistry | 4 | 2007 | 972 | 0.050 |
Why?
| | Immunotherapy | 1 | 2005 | 235 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 424 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2014 | 1587 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2004 | 211 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2007 | 600 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1028 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 47 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 53 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 63 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 86 | 0.040 |
Why?
| | Cell Line, Tumor | 3 | 2007 | 1388 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 702 | 0.040 |
Why?
| | Claudin-3 | 2 | 2007 | 5 | 0.030 |
Why?
| | Claudin-4 | 2 | 2007 | 7 | 0.030 |
Why?
| | Mice, SCID | 2 | 2007 | 173 | 0.030 |
Why?
| | Lymphocyte Activation | 2 | 2007 | 171 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 234 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 256 | 0.030 |
Why?
| | Apoptosis | 1 | 2020 | 1092 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2014 | 143 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 96 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 90 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2007 | 638 | 0.030 |
Why?
| | Optics and Photonics | 1 | 2013 | 11 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2014 | 146 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2005 | 314 | 0.030 |
Why?
| | Spectrum Analysis | 1 | 2013 | 71 | 0.030 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2013 | 49 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2005 | 1099 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 163 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 114 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 167 | 0.020 |
Why?
| | Prognosis | 2 | 2005 | 1956 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 12 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 84 | 0.020 |
Why?
| | Mast Cells | 1 | 2007 | 54 | 0.020 |
Why?
| | Remission Induction | 1 | 2007 | 205 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 136 | 0.020 |
Why?
| | Lymphocytes | 1 | 2007 | 154 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 215 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2007 | 482 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 2005 | 19 | 0.020 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2005 | 31 | 0.020 |
Why?
| | Sampling Studies | 1 | 2005 | 37 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2005 | 43 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 223 | 0.020 |
Why?
| | Probability | 1 | 2005 | 163 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2005 | 54 | 0.020 |
Why?
| | Paraffin Embedding | 1 | 2005 | 52 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 193 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 182 | 0.020 |
Why?
| | Carboplatin | 1 | 2004 | 51 | 0.020 |
Why?
| | Etoposide | 1 | 2004 | 71 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2005 | 212 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2007 | 470 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2005 | 175 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2004 | 121 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 120 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2005 | 462 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 456 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 579 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 404 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 1578 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 409 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 4029 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2005 | 328 | 0.010 |
Why?
| | Clinical Competence | 1 | 2006 | 395 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 858 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2006 | 1128 | 0.010 |
Why?
| | Survival Rate | 1 | 2005 | 905 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 385 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2003 | 450 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 1092 | 0.010 |
Why?
| | Rats | 1 | 2007 | 3273 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 1254 | 0.010 |
Why?
| | Child | 1 | 2004 | 6844 | 0.010 |
Why?
|
|
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|